Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
ABSTRACT Matrix metalloproteinases (MMPs) are cytokine-modulated enzymes that play an important role in the pathogenesis of rheumatoid arthritis (RA) by inducing bone resorption and cartilage destruction. This study evaluated the modulation of serum and synovial MMPs and their inhibitor, tissue inhibitor of matrix metalloproteinases (TIMP)-1, by therapy with soluble tumour necrosis factor (TNF) alpha receptor (etanercept).
Serum samples were collected from 60 RA patients at baseline and after 8 or 12 weeks of treatment. Paired synovial biopsies were obtained from 11 patients at two time points, before and after 8 weeks of treatment. We measured serum levels of MMP-1, MMP-3 and TIMP-1 by ELISA. Immunohistological analysis of synovial tissue was performed using monoclonal antibodies specific for MMP-1, MMP-3 and TIMP-1.
Etanercept therapy significantly down-regulated serum levels of MMP-3 and MMP-1 in parallel with the reduction in inflammatory parameters (C-reactive protein concentration and erythrocyte sedimentation rate) in RA patients. Baseline pretreatment serum levels of MMP-3 correlated with changes in clinical disease activity during therapy. No consistent changes in serum level of TIMP-1 were observed, while ratios of MMP-1 and MMP-3 to TIMP-1 were down-regulated following etanercept treatment. Immunohistochemical analyses revealed great interindividual variability, with generally a high level of expression of MMP and low expression of TIMP. No significant change in the pattern or number of positive cells occurred during therapy.
In RA patients, etanercept therapy down-regulates serum levels of MMP-3 and MMP-1 and the ratio between MMPs and TIMP-1. This may be an important mechanism for the prevention of future development of joint damage.
- SourceAvailable from: James F Leary[Show abstract] [Hide abstract]
ABSTRACT: The concept of personalized medicine has recently emerged as a promising way to address unmet medical needs. Due to the limitations of standard diagnostic and therapeutic strategies, the disease treatment is moving towards tailored treatment for individual patients, considering the inter-individual variability in therapeutic response. Theranostics, which involves the combination of therapy and diagnostic imaging into a single system, may fulfill the promise of personalized medicine. By integrating molecular imaging functionalities into therapy, theranostic approach could be advantageous in therapy selection, treatment planning, objective response monitoring and follow-up therapy planning based on the specific molecular characteristics of a disease. Although the field of therapy and imaging of its response have been independently developed thus far, developing imaging strategies can be fully exploited to revolutionize the theranostic systems in combination with the therapy modality. In this review, we describe the recent advances in molecular imaging technologies that have been specifically developed to evaluate the therapeutic efficacy for theranostic purposes.Journal of Controlled Release 04/2014; · 7.63 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Among various pro-inflammatory cytokines involved in the pathogenesis of rheumatoid arthritis (RA), tumor necrosis factor (TNF)-α plays a pivotal role in release of other cytokines and induction of chronic inflammation. Even though siRNA has the therapeutic potential, they have a challenge to be delivered into the target cells because of their poor stability in physiological fluids. Herein, we design a nanocomplex of polymerized siRNA (poly-siRNA) targeting TNF-α with thiolated glycol chitosan (tGC) polymers for the treatment of RA. Poly-siRNA is prepared through self-polymerization of thiol groups at the 5´ end of sense and anti-sense strand of siRNA and encapsulated into tGC polymers, resulting in poly-siRNA-tGC nanoparticles (psi-tGC-NPs) with an average diameter of 370 nm. In the macrophage culture system, psi-tGC-NPs exhibit rapid cellular uptake and excellent in vitro TNF-α gene silencing efficacy. Importantly, psi-tGC-NPs show the high accumulation at the arthritic joint sites in collagen-induced arthritis (CIA) mice. Treatment monitoring data obtained by the matrix metalloproteinase 3-specific nanoprobe and micro-computed tomography show that intravenous injection of psi-tGC-NPs significantly inhibits inflammation and bone erosion in CIA mice, comparable to methotrexate (5 mg/kg). Therefore, the availability of psi-tGC-NP therapy that target specific cytokines may herald new era in the treatment of RA.Molecular Therapy (2013); doi:10.1038/mt.2013.245.Molecular Therapy 10/2013; · 7.04 Impact Factor
Article: [Etanercept].[Show abstract] [Hide abstract]
ABSTRACT: Etanercept (Enbrel, Wyeth Pharmaceuticals) is a fusion protein composed of a soluble TNF alpha receptor issued from bio-technology. It is a member of TNF alpha's family with two others marked infliximab (Remicade, Scheringh Plough Laboratory), chimeric monoclonal antibody (25 p. 100 mouse) and adalimumab (Humira, Abbott France Laboratory), humanized monoclonal antibody (100 p. 100 human). In United States, etanercept is approved by Food and Drug Administration, since 1998, to treat rheumatoid arthritis showing an inadequate response to prior therapy with other disease-modifying antirheumatic drugs (DMARDS). In France, the MA (Marketing Authorization) is more recent, in 2000, etanercept to treat active rheumatoid arthritis who showed an inadequate response to others DMARDS (like methotrexate for example), with opportunity, in 2002, to administer etanercept in active, severe RA, in first line treatment without previous use of methotrexate. Others MA have been obtained in ankylosing spondylitis (2004) polyarticular-course juvenile rheumatoid arthritis (2000), and in the treatment of psoriasic arthritis (2002). Request of MA have been realised to treat cutaneous mild to severe psoriasis in adult, which failed to respond, contradication or no tolerance with systemic treatment as methotrexate, cyclosporine or phototherapy. Among the others anti-TNF therapy, only infliximab can be prescribed, in dermatology, to treat psoriatic arthritis in France. Encouraging good results were the subject of cases report, but lacking clinical trial, predicting probably administration of etanercept in others indications in future. TNF alpha is a proinflammatory cytokine and plays an important role in the physiopathology of large inflammatory diseases. Logically, in future, we should increased prescription of biotherapy, particularly anti-TNF alpha. We have to mind short or mild-term adverse events, widely described in the literature, but long-term side effects remained unknown. Moreover, these biotherapic agents have a high cost and should be estimate.Annales de Dermatologie et de Vénéréologie 12/2005; 132(11 Pt 1):861-76. · 0.60 Impact Factor
Anti-tumour necrosis factor (TNF)-a therapy
(etanercept) down-regulates serum matrix
metalloproteinase (MMP)-3 and MMP-1 in
A. I. Catrina, J. Lampa, S. Ernestam1, E. af Klint, J. Bratt1,
L. Klareskog and A.-K. Ulfgren
Department of Rheumatology, Karolinska Hospital and1Department of
Rheumatology, Huddinge Hospital, Stockholm, Sweden
Objectives. Matrix metalloproteinases (MMPs) are cytokine-modulated enzymes that play an
important role in the pathogenesis of rheumatoid arthritis (RA) by inducing bone resorption and
cartilage destruction. This study evaluated the modulation of serum and synovial MMPs and
their inhibitor, tissue inhibitor of matrix metalloproteinases (TIMP)-1, by therapy with soluble
tumour necrosis factor (TNF) a receptor (etanercept).
Methods. Serum samples were collected from 60 RA patients at baseline and after 8 or
12 weeks of treatment. Paired synovial biopsies were obtained from 11 patients at two time
points, before and after 8 weeks of treatment. We measured serum levels of MMP-1, MMP-3 and
TIMP-1 by ELISA. Immunohistological analysis of synovial tissue was performed using
monoclonal antibodies specific for MMP-1, MMP-3 and TIMP-1.
Results. Etanercept therapy significantly down-regulated serum levels of MMP-3 and MMP-1
in parallel with the reduction in inflammatory parameters (C-reactive protein concentration and
erythrocyte sedimentation rate) in RA patients. Baseline pretreatment serum levels of MMP-3
correlated with changes in clinical disease activity during therapy. No consistent changes in
serum level of TIMP-1 were observed, while ratios of MMP-1 and MMP-3 to TIMP-1 were
down-regulated following etanercept treatment. Immunohistochemical analyses revealed great
interindividual variability, with generally a high level of expression of MMP and low expression
of TIMP. No significant change in the pattern or number of positive cells occurred during
Conclusions. In RA patients, etanercept therapy down-regulates serum levels of MMP-3 and
MMP-1 and the ratio between MMPs and TIMP-1. This may be an important mechanism for
the prevention of future development of joint damage.
KEY WORDS: Rheumatoid arthritis, Soluble tumour necrosis factor a receptor, Etanercept,
Metalloproteinases, Tissue inhibitors of metalloproteinases.
Rheumatoid arthritis (RA) is an autoimmune inflam-
matory disease characterized by cartilage destruction
and extracellular matrix degradation. Cytokines, such
as tumour necrosis factor (TNF)-a and interleukin
(IL)-1, play a major role in the pathogenesis of the
disease, being able to induce bone resorption and
cartilage destruction (for review see w1x). These two
cytokines act synergistically to release matrix metallo-
proteinases (MMPs), a class of zinc-dependent pep-
tidases participating in extracellular matrix degradation
and remodelling. MMPs are synthesized and secreted
as latent pro-enzymes and their activation is due to
proteolysis of a pro-peptide domain at the N-terminus
of the molecule.
At present there are at least 19 known human MMPs,
which can be divided into four groups: the collagenases,
the stromelysins, the gelatinases and the membrane-
type MMPs (for review see w2x). Stromelysin 1 (MMP-3)
and collagenase (MMP-1) are thought to be probably
involved in the pathogenesis of RA w3x. MMP-3 levels
are increased both in synovial fluid w4x and serum w5x
in RA patients, with a highly significant correlation
between matched samples w6x, suggesting that serum
MMP-3 is derived mainly from that synthesized in the
synovium. MMP-1 (fibroblast collagenase) is detected in
Submitted 1 May 2001; revised version accepted 2 November 2001.
? 2002 British Society for Rheumatology
RA synovial fluid w7x and serum samples w8x at higher
levels than in healthy controls. Tissue inhibitor of matrix
metalloproteinase (TIMP)-1 is a specific inhibitor of
MMPs. It is present in RA synovium to a lesser extent
compared with MMPs, suggesting imbalance between
the two components w9x.
Treatment with TNF blocking agents, alone or in
combination with methotrexate, has high clinical effi-
cacy and delays joint destruction in RA (for review
see w1x). Two TNF blocking agents are available for
clinical use: infliximab (a chimeric monoclonal anti-
body) and etanercept (a recombinant TNF receptor–Fc
fusion protein). Several mechanisms have been pro-
posed to explain the clinical efficacy of infliximab, such
as decreased cell recruitment at the site of inflam-
mation w10x, down-regulation of synovial cytokine
expression w11x and reduction of MMP-1 and MMP-3
synthesis w12x. However, it is not known if etanercept
therapy modulates the serum levels of MMPs and
TIMP, and there are no reports on parallel studies of
MMPs and TIMP in serum and synovial tissue during
TNF blockade either for etanercept or for infliximab.
Materials and methods
Patients and samples
Sixty patients (50 females and 10 males, median age
53 yr, range 30–80 yr) meeting the American College
of Rheumatology (ACR) criteria for RA w13x were
recruited for this study. All patients had a history of
failed therapy with at least one disease-modifying
anti-rheumatic drug (DMARD) at trial entry. No
patient received more than 10 mg prednisolone daily.
All patients received a subcutaneous injection of
25 mg etanercept (Wyeth-Ayerst, Philadelphia, PA,
USA) twice a week. Twenty-five patients were treated
with etanercept alone. Thirty-two patients received
etanercept in combination with methotrexate and cyclo-
sporin, one patient etanercept in combination with
sulphasalazine, and one patient etanercept in combina-
tionwith Reumacon (podophyllum)
Uppsala, Sweden), an anti-rheumatic agent w14x used on
a licence basis in Sweden.
Serum samples were collected from all 60 patients
before treatment and after 8 weeks of treatment
(23 patients, group 1) or after 12 weeks of treatment
(37 patients, group 2). Serum samples were stored
at 2208C until assayed. Synovial biopsies were obtained
at arthroscopy from 11 patients in group 1 before
treatment and after 8 weeks of treatment.
Clinical and laboratory assessments
All patients were assessed for overall activity of the
disease using the (disease activity score) DAS28 w15x
before treatment and after 12 weeks of treatment.
Changes in DAS28 score during therapy were calculated
as the difference between the estimated value after
12 weeks of treatment and the baseline pretreatment
value. The ACR response w16x to therapy was also
recorded after 12 weeks of treatment for all 60 patients.
Laboratory parameters, namely C-reactive protein
(CRP) concentration and erythrocyte sedimentation
rate (ESR), were recorded before and after 12 weeks
of treatment for all 60 patients.
Serum levels of MMP-1, MMP-3 and TIMP-1 were
(ELISA) (Amersham Pharmacia Biotech, Uppsala,
Sweden) according to the manufacturer’s directions.
Serum samples were diluted (1:1 for MMP-1, between
1:1 and 1:8 for MMP-3 and between 1:10 and 1:20 for
TIMP-1) and individual samples were assayed in duplic-
ate. The MMP-1 kit recognized total human MMP-1,
free MMP-1 and MMP-1 complexed with TIMP-1, but
not MMP-1 complexed with a2-macroglobulin. The
range of the assay was 6.25–100 nguml with sensitivity of
1.7 nguml. The MMP-3 assay recognized proMMP-3,
active MMP-3 and MMP-3uTIMP complexes but not
MMP-3 bound by a2-macroglobulin, in the range
3.75–120 nguml with sensitivity of 2.35 nguml. Total
TIMP-1 (free TIMP-1 and TMP-1 complexed with
MMPs) was recognized by ELISA in the range
3.13–50 nguml with sensitivity of 1.25 nguml. Ratios
of MMP-3 to TIMP-1 and MMP-1 to TIMP-1 were
Tissue preparation and immunohistochemical analysis
Eleven patients from group 1 were subjected to knee
arthroscopy before treatment and after 8 weeks of
treatment. Biopsy specimens adjacent to the cartilage–
pannus junction were snap-frozen in liquid nitrogen
and then kept at 2708C until sectioned. Serial cryostat
sections (7 mm) were fixed for 20 min with 2% (vuv)
formaldehyde (Sigma Chemicals, St Louis, MO, USA)
and stored at 2708C. The staining procedure has been
published previously w17x. We used the following mouse
monoclonal antibodies (all purchased from Oncogene,
Cambridge, MA, USA): anti-MMP-1 IgG2a (41-1E5),
anti-MMP-3 IgG1 (55-2A4) and anti-TIMP-1 IgG1
(7-6C1). Negative controls with matched IgG isotype
included for each marker w17x.
Stained synovial biopsy sections were evaluated
using computerized image analysis as described pre-
viously w18x. The areas of MMP and TIMP staining were
expressed as percentages of the total area of counter-
stained tissue. Analysis of an entire tissue section
typically involved 30–100 microscopic fields at a
magnification of 3250.
Differences between groups were analysed using the
Mann–Whitney U-test and analysis for matched pairs
was performed using Wilcoxon’s signed rank test.
Correlations between variables were assessed using
the Spearman rank correlation test. P<0.05 was
considered statistically significant.
Etanercept down-regulates MMP-3 and MMP-1 in RA
After 12 weeks of treatment, 47 of 60 patients (78.33%)
fulfilled ACR20 criteria, while 13 of 60 patients (21.66%)
showed no response to therapy. Clinical and laboratory
parameters improved significantly after 12 weeks of
treatment in all 60 patients, with reduction of the
DAS28 score wfrom 6.01 to 4.02 (median values),
P<0.0001x, CRP level wfrom 34 mguml to 15 mguml
(median values), P<0.0001x and ESR wfrom 42 to
27 mmuh (median values), P<0.0001x.
Serum levels of MMPs and TIMPs
Table 1 summarizes the results of ELISA analyses.
Following treatment, the median serum level of MMP-3
decreased significantly in group 1 of patients from 68.1
to 46.5 nguml (P<0.001) and in group 2 of patients
from 115.3 to 48.8 nguml (P<0.0001). The median
serum level of MMP-1 decreased significantly in group 1
patients from 9.3 to 8.7 nguml (P<0.05) and in group 2
patients from 9.8 to 7.9 nguml (P=0.001). The median
serum level of TIMP-1 was down-regulated following
8 weeks of treatment for patients in group 1 (from 433.2
to 371.6 nguml, P<0.05) but remained unchanged
compared with the baseline value after 12 weeks for
patients in group 2 (Table 1 and Fig. 1). In group 1, the
MMP-1:TIMP-1 and MMP-3:TIMP-1 ratios were not
significantly changed after 8 weeks of treatment. In
group 2, both the median MMP-1:TIMP-1 ratio and the
median MMP-3:TIMP-1 ratio decreased significantly
wfrom 0.025 to 0.020 (P<0.05) for MMP-1:TIMP-1
(Table 1 and Fig. 2).
We did not observe any difference between cortisone-
treated and non-treated patients or between patients
treated with DMARDs and those not treated with
TABLE 1. Serum levels of MMP-3, MMP-1 and TIMP-1 and their ratios before treatment (week 0) and after 8 weeks of treatment (group 1) or after
12 weeks of treatment (group 2)
Group 1Group 2
Week 0Week 8 Week 0 Week 12
Values are median (range).
FIG. 1. Changes in serum levels of MMP-3 (A), MMP-1 (B)
and TIMP-1 (C) during etanercept treatment in group 1 (white
boxes) and group 2 (grey boxes). Horizontal lines represent
medians and whiskers the non-outlier values. *P<0.05;
**P<0.01; ***P<0.001 (non-parametric Mann–Whitney
A. I. Catrina et al.
Correlations between serum levels of MMPs and
TIMP-1 and disease parameters
In all 60 patients, the serum level of MMP-3 before
treatment correlated with the baseline CRP level
(P<0.001, r=0.42) and baseline ESR (P<0.01,
r=0.38) (data not shown). Moreover, the baseline
serum level of MMP-3 correlated with the change in
FIG. 2. ChangesinMMP-1:TIMP-1(A)andMMP-3:TIMP-1
(B) ratios during etanercept treatment in group 1 (white boxes)
and group 2 (grey boxes). Horizontal lines represent medians
and whiskers the non-outlier values. *P<0.05; ***P<0.001
(non-parametric Mann–Whitney U-test).
TABLE 2. Synovial expression of MMP-1, MMP-3 and TIMP-1 before
treatment and after 8 weeks of etanercept treatment in 11 patients
Positive cells (%)
Week 0Week 8
Values are median percentage of positive cells (percentage of
positively stained area as a percentage of total counterstained area)
evaluated by computer image analysis, with ranges in parentheses.
FIG. 3. Photographs illustrating brown immunoperoxidase staining for MMPs and TIMP-1 in serial sections from cryopreserved
synovial biopsies counterstained with haematoxylin. (A) MMP-1. (B) MMP-3. (C) TIMP-1. Original magnification 3310. All
sections are from the same patient before treatment.
Etanercept down-regulates MMP-3 and MMP-1 in RA
DAS score after 12 weeks of treatment (P<0.05,
r=20.28) (data not shown).
Pretreatment serum level of TIMP-1 correlated with
baseline CRP level (P<0.001, r=0.43) and ESR
(P<0.01, r=0.34) (data not shown). Pretreatment
serum level of MMP-1 did not correlate with any
Table 2 summarizes the results of immunohistochemical
analysis of the biopsies obtained from 11 patients in
group 1 at baseline and after 8 weeks of treatment. We
observed great inter-individual variability even though
most patients had a high level of MMP expression and a
low level of TIMP expression (Fig. 3). Matrix metallo-
proteinases were present in all biopsies studied, both
before and after treatment, while TIMP-1 was identified
in 20 out of 22 biopsies investigated.
MMP-3 was present mainly in the lining and endo-
thelial cells. MMP-1 was expressed mainly in the sub-
lining layer and around vessels and to a lesser extent in
the lining layer. TIMP-1 showed a generally low level
of expression, with positive signal in isolated areas.
No significant changes in the pattern or number of
positive cells occurred after 8 weeks of treatment.
MMPs have a major role in RA pathogenesis as
mediators of cartilage and bone destruction, and this
is the first report describing modulation of the MMP–
TIMP system by soluble TNF-a receptors (etanercept)
in RA patients.
We focused our study on MMP-3 and MMP-1,
measuring their serum levels with ELISA kits that
recognized both the active and inactive forms of MMPs.
Serum levels of MMP-3 quantified by this method
have been shown previously to correlate with radio-
logical damage w19–20x in RA patients. We found that
etanercept therapy significantly decreased the serum
level of MMP-3 as well as the ratio of MMP-3 to
TIMP-1. These changes could explain the ability of anti-
TNF therapy to prevent further development of joint
damage. Serum levels of MMP-3 correlated highly with
inflammatory markers (CRP and ESR), as shown pre-
viously w8, 21x. Moreover, our data indicate that baseline
MMP-3 serum levels may predict the changes in DAS
score during therapy.
We also observed a decrease in the serum level of
MMP-1 during etanercept therapy, with reduction of the
MMP-1:TIMP-1 ratio. It was shown previously that
the serum level of MMP-1 correlated with the number
of new erosions that developed in RA patients over
18 months of follow-up w22x. Thus, the decrease in the
serum level of MMP-1 could partly explain the delay
in radiological progression in patients with RA during
etanercept treatment. The serum level of MMP-1 did not
correlate with inflammatory parameters, suggesting that
the effect of etanercept on the serum level of MMP-1 is
independent of the down-regulation of inflammation.
The serum level of TIMP-1 before treatment correl-
ated with both CRP and ESR. Interestingly, etanercept
therapy did not influence the serum level of TIMP-1 con-
sistently despite a general decrease in all inflammatory
markers investigated. This finding suggests that TIMP-1
is influenced mainly by a pro- anduor anti-inflammatory
mechanism other than one involving TNF.
Several reports have suggested that there might be
an imbalance between MMP and TIMP expression in
the RA synovium w3x, allowing MMP activation and
the subsequent destruction of joint components. A
recent study reported that a high level of synovial
expression of MMP-1 mRNA in early RA distinguished
patients with more rapidly progressive erosive disease
w23x. We did not observe any changes in the synovial
expression of MMPs and TIMP-1 during etanercept
therapy, however, even though biopsies were taken
from areas adjacent to the cartilage pannus junction.
Possible explanations for this finding are the low
number of patients subjected to arthroscopy anduor
lack of specificity between the recognition of active
and inactive forms of MMPs.
In conclusion, we have demonstrated that therapy
with soluble TNF-a receptors significantly decreases the
serum levels of MMP-3 and MMP-1, with reductions
in the ratios of MMPs to TIMP-1. The pretreatment
serum level of MMP-3 may be considered a potential
predictor of changes in clinical disease activity during
treatment with etanercept.
We thank Associate Professor R. A. Harris for linguistic
advice. Marianne Engstrom provided excellent technical
assistance. The study was supported by grants from
the Swedish Medical Research Council, the Swedish
Rheumatism Association, the insurance company AMF
and from Freemasan Barnhuset Stockholm.
rheumatoid arthritis. Annu Rev Med 2000;51:207–29.
2. Curran S, Murray GI. Matrix metalloproteinases in
tumour invasion and metastasis. J Pathol 1999;189:300–8.
3. Firestein GS. Etiology and pathogenesis of rheumatoid
arthritis. In: Kelley WN, Harris ED Jr, Ruddy S,
Sledge CB, eds. Textbook of Rheumatology, Vol. 1, 5th
edn. Philadelphia: W.B. Saunders, 1997:851–97.
4. Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H. Deter-
mination of stromelysin-1, 72 and 92 kDatype IVcollagen-
ase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and
TIMP-2 in synovial fluid and serum from patients with
rheumatoid arthritis. J Rheumatol 1996;23:1599–604.
5. Zucker S, Lysik RM, Zarrabi MH et al. Elevated plasma
stromelysin levels in arthritis wsee commentsx. J Rheumatol
6. Yoshihara Y, Obata K, Fujimoto N, Yamashita K,
Hayakawa T, Shimmei
stromelysin-1 and tissue inhibitor of metalloproteinases-1
in sera from patients with rheumatoid arthritis. Arthritis
RN, TaylorPC. Anti-cytokinetherapy for
M. Increasedlevels of
A. I. Catrina et al.